Overview

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

Status:
Completed

Trial end date:
2019-10-10

Target enrollment:

Participant gender:

Summary

This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis lesions on the face or balding scalp.

Phase:

Phase 1

Details

Lead Sponsor:

Athenex, Inc.

Collaborator:

TKL Research, Inc.

Treatments:

Tirbanibulin